• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ascendis Pharma ADR (NQ: ASND )

    124.54 +1.72 (+1.40%)
    Streaming Delayed Price Updated: 11:40 AM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ascendis Pharma ADR

    < Previous 1 2 3 4 5 6 7 Next >
    63 Biggest Movers From Yesterday
    Gainers Support.com, Inc. (NASDAQ: SPRT) shares surged 41.1% to settle at $19.70 on Thursday on abnormally high volume. TSR, Inc. (NASDAQ: TSRI) shares rose 28.1% to close at $11... 
    Via Benzinga
    Why Shares of Ascendis Soared This Week
    The pharmaceutical company saw its shares jump more than $26. 
    Via The Motley Fool
    The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
    Via Benzinga
    Exposures COVID-19
    Expert Ratings For Ascendis Pharma
    Ascendis Pharma (NASDAQ:ASND) has observed the following ... 
    Via Benzinga
    Mid-Afternoon Market Update: Pure Storage Rises Following Strong Q2 Results; SelectQuote Shares Plunge
    Toward the end of trading Thursday, the Dow traded down 0.38% to 35,270.96 while the NASDAQ fell 0.35% to 14,988.64. The S&P also fell, dropping 0.40% to 4,483.22. The U.S.... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Here's Why Ascendis Pharma Shares Are Surging Higher Today
    Approval of the company's weekly growth hormone is making investors smile today. 
    Via The Motley Fool
    What 8 Analyst Ratings Have To Say About Ascendis Pharma
    Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings w... 
    Via Benzinga
    Mid-Day Market Update: Dow Tumbles Over 100 Points; Ascendis Pharma Shares Spike Higher
    Midway through trading Thursday, the Dow traded down 0.33% to 35,288.79 while the NASDAQ fell 0.62% to 14,948.24. The S&P also fell, dropping 0.53% to 4,472.56. The U.S. has... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    45 Stocks Moving In Thursday's Mid-Day Session
    Gainers Blue Water Acquisition Corp. (NASDAQ: BLUW) shares climbed 57% to $16.41. Blue Water Acquisition is expected to hold a special meeting of its stockholders on Friday,... 
    Via Benzinga
    See Why Ascendis Pharma Stock Is Shining On Thursday
    The FDA on Wednesday gave a thumbs-up to Ascendis Pharma A/S's (NASDAQ: ASND) long-acting growth hormone lonapegsomatropin-tcgd. Marketed as Skytrofa, the... 
    Via Benzinga
    Exposures Product Safety
    Ascendis Stock Surges To 6-Month High; FDA Approval Lands It In A Major Market
    Ascendis Pharma won FDA approval to treat children with insufficient growth hormone, and the biotech stock rocketed on Thursday. 
    Via Investor's Business Daily
    Exposures Product Safety
    Mid-Morning Market Update: Markets Mixed; Dollar General Profit Beats Views
    Following the market opening Thursday, the Dow traded up 0.15% to 35,458.00 while the NASDAQ rose 0.02% to 15,044.79. The S&P, however, dropped 0.12% to 4,490.91. The U.S. has... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Recap: Ascendis Pharma Q2 Earnings
    Shares of Ascendis Pharma (NASDAQ:ASND) rose 23.2% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 38.71% year over... 
    Via Benzinga
    The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)... 
    Via Benzinga
    Exposures COVID-19
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Gainers Ascendis Pharma (NASDAQ:ASND) stock increased by 22.69% to $151.73 during Thursday's pre-market session. The company's market cap stands at $8.1 billion.... 
    Via Benzinga
    22 Stocks Moving in Thursday's Pre-Market Session
    Gainers Good Works Acquisition Corp. (NASDAQ: GWAC) rose 29.8% to $13.01 in pre-market trading. Good Works Acquisition and Cipher Mining reported shareholder approval of business... 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Gainers Ascendis Pharma (NASDAQ:ASND) st... 
    Via Benzinga
    The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
    ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
    Via Benzinga
    Exposures COVID-19
    Earnings Scheduled For August 25, 2021
    Companies Reporting Before The Bell • Jiayin Gr (NASDAQ:JFIN) is projected to report quarterly earnings at $0.21 per share on revenue of $54.80 million. • Viomi... 
    Via Benzinga
    The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More
    Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues,... 
    Via Benzinga
    Exposures Product Safety
    The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
    Via Benzinga
    The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... 
    Via Benzinga
    The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
    Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
    Via Talk Markets
    Exposures Product Safety
    The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated... 
    Via Benzinga
    The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
    Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
    Via Benzinga
    Exposures Product Safety
    Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months
    The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S's (NASDAQ: ASND) TransCon hGH (lonapegsomatropin) for the... 
    Via Benzinga
    Exposures Product Safety
    Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
    The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
    Via Benzinga
    Exposures Product Safety
    What 5 Analyst Ratings Have To Say About Ascendis Pharma
    Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1... 
    Via Benzinga
    Earnings Scheduled For June 1, 2021
    Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is expected to report quarterly loss at $0.11 per share on revenue of $10.82 million. • Canopy... 
    Via Benzinga
    Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript
    ASND earnings call for the period ending March 31, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.